IGMPI Approvals & Accreditation : Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India, Approved Training Institute of Food Safety and Standards Authority of India (FSSAI), Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India, An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh, Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC)
Trusted by organizations & training participants in over 30 countries. Training | Certification | Education | Research

Positive Results demonstrating Improvement in Disability and Quality of Life through Fremanezumab Phase IIIb FOCUS study

02nd July 2019

Teva Pharmaceutical Industries Ltd. announced the FOCUS (Phase IIIb Study of Fremanezumab) exploratory endpoints results at the 5th Congress of the European Academy of Neurology.

The first timed shared endpoints at EAN concluded the presentation of endpoints which were pre-specified from the Phase IIIb FOCUS study. This study accessed the efficacy and safety of Fremanezumab for the prevention treatment of migraine in adult patients who previously experienced inadequate responses to two to four classes of these treatments.

These results showed abatement in monthly average migraine days; cutback in migraine related symptoms; and progression in depression status; work productivity and activity impairment.

Migraine is a neurological disease which is disabling and is characterized by acute head pain, nausea and vomiting. It is the second leading cause of years lived with disability worldwide with profound brunt on patients, their friends and family, and on society as a whole. FOCUS study data unveiled the Fremanezumab results on a range of quality of life and disability measures as well as showing a significant abatement in the number of hours of headache and suffering days by patients and on a spectrum of associated symptoms.

For further enquiries, write to or call us on:
info@igmpiindia.org/ +91 8587838177, +91 8130924488, 0120-2427175, 0120-4375280

Pharmaceuticals | Food | Clinical Research | Healthcare | Medical Coding | Medical Device | Nanotechnology | IPR

Clinical Research Newsletter

Featured Article

GMP: A continous process

Mr Vinod Arora, Principal Advisor, IGMPI

IGMPI Placement Blog

Placement Testimonials

Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like